一、更正内容 1、《2025 年半年度募集资金存放与使用情况的专项报告》之"一、募集资 金基本情况"之"（二）本年度使用金额及结余情况" 更正前： 上海毕得医药科技股份有限公司 关于 2025 年半年度募集资金存放与使用情况的专项报告的更正公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海毕得医药科技股份有限公司（以下简称"公司"）于 2025 年 8 月 22 日 在上海证券交易所网站（www.sse.com.cn）披露了《2025 年半年度募集资金存放 与使用情况的专项报告》，经事后核查，本报告有部分内容存在错误。公司董事 会及管理层高度重视，第一时间组织财务人员进一步核查及确认，并对相关数据 予以更正，具体更正信息如下： 证券代码：688073 证券简称：毕得医药 公告编号：2025-079 截至 2025 年 06 月 30 日，结余募集资金（含利息收入扣除银行手续费的净 额）余额为 8,530.62 万元（其中：募集资金专户余额 929.90 万元；银行 7 天通 知存款和定期存款余额 7,600.72 ...

格隆汇9月12日丨毕得医药(688073.SH)公布，因股东自身流动性需求，股东李怡静、陈俊、李黎、杜 鹃、李爱飞、耿勇、蒋亚妹计划根据市场情况拟于本减持计划披露之日起3个交易日后的3个月内通过集 中竞价方式减持其所持有的公司股份，减持数量不超过公司总股本的1.00%。其中，李怡静减持公司股 份数量不超过227,854股，即不超过公司总股本的0.25%；陈俊减持公司股份数量不超过136,395股，即 不超过公司总股本的0.15%；李黎减持公司股份数量不超过136,395股，即不超过公司总股本的0.15%； 杜鹃减持公司股份数量不超过136,395股，即不超过公司总股本的0.15%；李爱飞减持公司股份数量不超 过131,836股，即不超过公司总股本的0.15%；耿勇减持公司股份数量不超过91,265股，即不超过公司总 股本的0.10%。蒋亚妹减持公司股份数量不超过47,960股，即不超过公司总股本的0.05%。减持价格将按 照减持实际实施时的市场价格确定。 ...

Company Profile and Key Financial Indicators This section provides an overview of the company's fundamental information, key financial performance, and non-recurring items, highlighting strong profit growth despite a decrease in operating cash flow [Company Basic Information](index=6&type=section&id=%E5%85%AC%E5%8F%B8%E5%9F%BA%E6%9C%AC%E6%83%85%E5%86%B5) Shanghai Bide Pharmaceutical Technology Co., Ltd. (Bide Pharma) is a company listed on the STAR Market of the Shanghai Stock Exchange, stock code 688073, primarily engaged in pharmaceutical technology with Dai Lan as its legal representative Company Basic Information | Item | Content | | :--- | :--- | | Chinese Name | Shanghai Bide Pharmaceutical Technology Co., Ltd. | | Chinese Abbreviation | Bide Pharma | | Stock Code | 688073 | | Listing Exchange | Shanghai Stock Exchange STAR Market | | Legal Representative | Dai Lan | [Key Accounting Data and Financial Indicators](index=7&type=section&id=%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) During the reporting period, the company achieved strong performance growth, with operating revenue increasing by 17.91% year-on-year and net profit attributable to shareholders surging by 41.60%, primarily due to increased revenue and effective cost control, though operating cash flow decreased significantly due to business expansion Key Accounting Data (Jan-Jun 2025) | Key Accounting Data | Current Period (Yuan) | Prior Year Period (Yuan) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 627,526,589.12 | 532,207,309.99 | 17.91 | | Net Profit Attributable to Shareholders | 73,406,059.54 | 51,839,064.55 | 41.60 | | Net Profit Attributable to Shareholders (Excl. Non-recurring Items) | 59,163,606.01 | 48,256,312.13 | 22.60 | | Net Cash Flow from Operating Activities | 16,112,188.59 | 89,677,429.18 | -82.03 | | **Asset Status** | **Period-End (Yuan)** | **Prior Year-End (Yuan)** | **Period-End vs. Prior Year-End Change (%)** | | Total Assets | 2,530,189,768.10 | 2,418,035,118.40 | 4.64 | | Net Assets Attributable to Shareholders | 1,948,725,654.19 | 2,027,122,463.64 | -3.87 | Key Financial Indicators (Jan-Jun 2025) | Key Financial Indicators | Current Period | Prior Year Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | Basic Earnings Per Share (Yuan/share) | 0.84 | 0.58 | 44.83 | | Weighted Average Return on Net Assets (%) | 3.60 | 2.52 | Increased by 1.08 percentage points | | R&D Investment as % of Operating Revenue | 4.78 | 5.65 | Decreased by 0.87 percentage points | [Non-recurring Gains and Losses Items and Amounts](index=9&type=section&id=%E9%9D%9E%E5%B8%B8%E8%A7%84%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%92%8C%E9%87%91%E9%A2%9D) During the reporting period, the company's total non-recurring gains and losses amounted to **14.24 million yuan**, primarily comprising government subsidies recognized in current profit and loss and fair value changes from holding and disposing of financial assets Details of Non-recurring Gains and Losses | Non-recurring Gains and Losses Item | Amount (Yuan) | | :--- | :--- | | Government subsidies recognized in current profit and loss | 9,655,087.56 | | Gains/losses from holding and disposing of financial assets/liabilities | 7,265,175.10 | | Gains/losses from disposal of non-current assets | 330,567.88 | | Other non-operating income and expenses | 226,535.89 | | **Total** | **17,477,366.43** | | Less: Income tax impact | 3,234,912.90 | | **Total after tax** | **14,242,453.53** | [Net Profit Excluding Share-based Payment Impact](index=10&type=section&id=%E6%89%A3%E9%99%A4%E8%82%A1%E4%BB%BD%E6%94%AF%E4%BB%98%E5%BD%B1%E5%93%8D%E5%90%8E%E7%9A%84%E5%87%80%E5%88%A9%E6%B6%A6) Excluding the impact of share-based payment expenses, the company's net profit for the reporting period was **89.68 million yuan**, a significant increase of **70.60%** from the prior year, better reflecting core business profitability Net Profit Comparison Excluding Share-based Payment Impact | Period | Net Profit Excluding Share-based Payment Impact (Yuan) | YoY Change (%) | | :--- | :--- | :--- | | Current Period (Jan-Jun) | 89,679,870.74 | 70.60 | | Prior Year Period | 52,566,039.57 | - | Management Discussion and Analysis This section details the company's industry, main business operations, operating performance, core competencies, R&D progress, and key risk factors, providing a comprehensive overview of its strategic positioning and operational dynamics [Explanation of the Company's Industry and Main Business Operations During the Reporting Period](index=10&type=section&id=%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%85%AC%E5%8F%B8%E6%89%80%E5%B1%9E%E8%A1%8C%E4%B8%9A%E5%8F%8A%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E6%83%85%E5%86%B5%E8%AF%B4%E6%98%8E) The company is a high-tech enterprise focused on the upstream of the new drug R&D value chain, specializing in the R&D, production, and sales of drug molecular building blocks and scientific reagents, serving global new drug R&D institutions with a vast product portfolio - Company's core business involves drug molecular building blocks and scientific reagents, serving critical stages of new drug R&D, with clients including multinational pharmaceutical companies like Roche, Merck, Pfizer, and CROs like Wuxi AppTec[31](index=31&type=chunk)[33](index=33&type=chunk) Global Drug R&D and Molecular Building Blocks Market Forecast | Market | 2024 Market Size | Annual Growth Rate | 2028/2029 Forecast | | :--- | :--- | :--- | :--- | | Global Drug R&D Investment | 147.7 billion USD | 7.9% | > 200 billion USD (2028) | | Global Molecular Building Blocks | 51.5 billion USD | 3.4% | > 60 billion USD (2029) | [Explanation of Main Business Operations](index=10&type=section&id=%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E6%83%85%E5%86%B5%E8%AF%B4%E6%98%8E) The company's main business is divided into molecular building blocks and scientific reagents, offering a comprehensive "basic material library" for drug R&D with extensive inventory and custom synthesis capabilities, alongside specialized reagents for target validation and synthesis optimization - Molecular building blocks business offers nearly a million products, with over **140,000 items in stock**, meeting customer demands for "massive screening, rapid supply, and customized empowerment"[32](index=32&type=chunk)[36](index=36&type=chunk) - Scientific reagents business features active small molecule compounds for target validation and catalysts/ligands for precise control in drug synthesis[37](index=37&type=chunk)[39](index=39&type=chunk) [Company's Industry Overview](index=12&type=section&id=%E5%85%AC%E5%8F%B8%E6%89%80%E5%B1%9E%E8%A1%8C%E4%B8%9A%E6%83%85%E5%86%B5) The company operates in the molecular building blocks and scientific reagents industry, closely tied to global drug R&D investment, with significant market sizes projected for both segments and increasing market share for Chinese enterprises amidst stratified competition Related Industry Market Size and Forecast | Industry Segment | 2024/2025 Market Size | CAGR | | :--- | :--- | :--- | | Global Molecular Building Blocks | 51.5 billion USD (2024) | 3.4% | | Global Chemical Reagents | >180 billion USD (2025) | 6.4% | | Global Life Science Reagents | 68.74 billion USD (2025) | 6.51% | | Global Active Small Molecule Compounds | 8 billion USD (2024) | 9.3% | [Discussion and Analysis of Operating Performance](index=13&type=section&id=%E7%BB%8F%E8%90%A5%E6%83%85%E5%86%B5%E7%9A%84%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) During the reporting period, the company achieved steady growth with operating revenue of **628 million yuan** (up 17.91%) and net profit attributable to shareholders of **73.41 million yuan** (up 41.60%), driven by global expansion, diversified products, and R&D innovation, with gross margin improving to **44.25%** 2025H1 Operating Performance Highlights | Indicator | Amount/Ratio | YoY Change | | :--- | :--- | :--- | | Operating Revenue | 628 million Yuan | +17.91% | | Net Profit Attributable to Shareholders | 73.41 million Yuan | +41.60% | | Net Profit Excluding Share-based Payment | 89.68 million Yuan | +70.60% | | Gross Margin | 44.25% | +4.74 percentage points | | Overseas Sales Revenue | - | +21.33% | - The company continuously expands its product range, covering hot R&D areas such as PROTAC, GLP-1, and XDC, with a product library of nearly a million items and over **140,000 items in stock**[47](index=47&type=chunk) [Analysis of Core Competencies During the Reporting Period](index=14&type=section&id=%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E6%A0%B8%E5%BF%83%E7%AB%9E%E4%BA%89%E5%8A%9B%E5%88%86%E6%9E%90) The company's core competencies are built on a vast product catalog, efficient customized synthesis, digital and intelligent operations, a high-margin product structure, and a strong global service network, collectively driving its competitive advantage in new drug R&D - The company has built a product catalog of nearly a million items, covering cutting-edge fields like PROTAC, ADC, and GLP-1, establishing itself as one of the global suppliers with the most extensive product lines for drug discovery reagents[49](index=49&type=chunk) - Leveraging advanced synthesis platforms and intelligent evaluation systems, the company provides end-to-end customized services, capable of completing specified structure synthesis and delivery within **2-4 weeks**[50](index=50&type=chunk) - Through its digital platform and e-commerce development, the company offers intelligent product search, one-click ordering, automatic COA/SDS generation, and full logistics tracking, enhancing customer experience and order conversion efficiency[51](index=51&type=chunk) [Core Technologies and R&D Progress](index=15&type=section&id=%E6%A0%B8%E5%BF%83%E6%8A%80%E6%9C%AF%E4%B8%8E%E7%A0%94%E5%8F%91%E8%BF%9B%E5%B1%95) The company possesses a comprehensive core technology system spanning product design, synthesis, production, and purification & detection, with significant R&D investment and a growing patent portfolio, demonstrating its commitment to innovation - The company's core technology platforms include: industry-leading molecular building block design and screening capabilities, rich and efficient organic synthesis technologies (e.g., C-H activation, chiral compound technology), and product purification and structural confirmation techniques[56](index=56&type=chunk)[60](index=60&type=chunk)[64](index=64&type=chunk) R&D Investment and Achievements | Indicator | Current Period | Prior Year Period | Change | | :--- | :--- | :--- | :--- | | Total R&D Investment (Yuan) | 29,996,679.58 | 30,050,598.68 | -0.18% | | R&D Investment as % of Revenue | 4.78 | 5.65 | Decreased by 0.87 percentage points | | **Intellectual Property** | **Newly Acquired in Current Period** | **Cumulatively Acquired** | - | | Invention Patents (units) | 3 | 54 | - | [Risk Factors](index=30&type=section&id=%E9%A3%8E%E9%99%A9%E5%9B%A0%E7%B4%A0) The company faces significant risks from intensifying market competition, potential intellectual property disputes, uncertainties in R&D commercialization, macroeconomic volatility, and financial challenges related to large inventory balances and exchange rate fluctuations - Market competition is intensifying, with product homogenization and price competition in mid-to-low-end segments posing major challenges[84](index=84&type=chunk) - Intellectual property risks include potential infringement disputes arising from customers' unauthorized use and the threat of imitation of the company's core compound database[85](index=85&type=chunk)[86](index=86&type=chunk) - Financial risks primarily involve a substantial inventory balance (book value of **851 million yuan** at period-end, accounting for **33.62%** of total assets) and exchange losses due to currency fluctuations (**2.78 million yuan** in exchange losses during the reporting period)[89](index=89&type=chunk) [Key Operating Performance During the Reporting Period](index=31&type=section&id=%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E4%B8%BB%E8%A6%81%E7%BB%8F%E8%90%A5%E6%83%85%E5%86%B5) During the reporting period, the company's main business achieved steady growth, with drug molecular building blocks revenue up 14.35% and scientific reagents revenue up 38.95%, while financial expenses increased significantly due to reduced interest income and exchange losses, and investment in wealth management products led to a substantial increase in trading financial assets Main Business Revenue Composition | Business Segment | Current Period Revenue (Million Yuan) | YoY Growth (%) | | :--- | :--- | :--- | | Drug Molecular Building Blocks | 520.46 | 14.35 | | Scientific Reagents | 107.07 | 38.95 | | **Total** | **627.53** | **17.91** | Key Financial Statement Item Changes | Item | Current Period Amount (Yuan) | Change (%) | Primary Reason | | :--- | :--- | :--- | :--- | | Financial Expenses | 4,178,143.31 | N/A | Reduced interest income from wealth management and exchange losses | | Net Cash Flow from Operating Activities | 16,112,188.59 | -82.03 | Business expansion, increased product procurement expenses | | Trading Financial Assets | 460,896,808.21 | 510.28 | Increased allocation to bank wealth management products | | Short-term Borrowings | 203,152,860.14 | 573.08 | Increase in bank short-term borrowings | Corporate Governance, Environment, and Society This section outlines significant changes in the company's leadership and core technical personnel, as well as the implementation details of its equity incentive plans, reflecting ongoing efforts in talent management and employee motivation [Changes in Directors, Senior Management, and Core Technical Personnel](index=40&type=section&id=%E5%85%AC%E5%8F%B8%E8%91%A3%E4%BA%8B%E3%80%81%E9%AB%98%E7%BA%A7%E7%AE%A1%E7%90%86%E4%BA%BA%E5%91%98%E5%92%8C%E6%A0%B8%E5%BF%83%E6%8A%80%E6%9C%AF%E4%BA%BA%E5%91%98%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) During the reporting period, the company experienced several changes in senior management and core technical personnel, including the resignation of Li Tao and Mao Yonghao, and the appointment of new CFO and Board Secretary, along with the addition of seven new core technical personnel to maintain R&D stability - Key personnel changes include the departure of Li Tao (Director, Board Secretary, CFO), and the appointment of Wang Kun as CFO and Wang Xuan as Board Secretary[111](index=111&type=chunk)[114](index=114&type=chunk)[115](index=115&type=chunk) - Core technical personnel Mao Yonghao resigned, and the company newly identified Zhang Ruihao and 6 others as core technical personnel to maintain R&D team stability[111](index=111&type=chunk)[112](index=112&type=chunk)[116](index=116&type=chunk) [Status and Impact of Company's Equity Incentive Plans, Employee Stock Ownership Plans, or Other Employee Incentive Measures](index=41&type=section&id=%E5%85%AC%E5%8F%B8%E8%82%A1%E6%9D%83%E6%BF%80%E5%8A%B1%E8%AE%A1%E5%88%92%E3%80%81%E5%91%98%E5%B7%A5%E6%8C%81%E8%82%A1%E8%AE%A1%E5%88%92%E6%88%96%E5%85%B6%E4%BB%96%E5%91%98%E5%B7%A5%E6%BF%80%E5%8A%B1%E6%8E%AA%E6%96%BD%E7%9A%84%E6%83%85%E5%86%B5%E5%8F%8A%E5%85%B6%E5%BD%B1%E5%93%8D) During the reporting period, the company implemented the grant of its 2024 restricted stock incentive plan, initially granting **2.06 million shares** to 65 recipients and later **0.494 million reserved shares** to 18 recipients, both at a price of **24.96 yuan per share** - On January 8, 2025, the company initially granted **2.06 million restricted shares** to 65 incentive recipients at a price of **24.96 yuan per share**[118](index=118&type=chunk) - On April 18, 2025, the company granted **0.494 million reserved restricted shares** to 18 incentive recipients at a price of **24.96 yuan per share**[118](index=118&type=chunk) Significant Matters This section covers the company's fulfillment of commitments, significant related party transactions, major contracts, and the progress of raised funds utilization, providing insight into its operational integrity and strategic financial management [Fulfillment of Commitments](index=43&type=section&id=%E6%89%BF%E8%AF%BA%E4%BA%8B%E9%A1%B9%E5%B1%A5%E8%A1%8C%E6%83%85%E5%86%B5) During the reporting period, the company's actual controllers, shareholders, related parties, and the company itself strictly fulfilled all commitments made during the initial public offering, including share lock-up, share price stabilization, avoidance of horizontal competition, and regulation of related party transactions, with no breaches observed - The company's controlling shareholders and actual controllers, Dai Lan and Dai Long, committed not to transfer pre-IPO shares for **36 months** from the listing date, with extended lock-up periods and reduced share price commitments linked to the offering price[122](index=122&type=chunk)[126](index=126&type=chunk) - The company, its controlling shareholders, directors, and senior management committed to initiating share price stabilization measures, including company buybacks, controlling shareholder增持, and director/senior management增持, if the share price falls below net asset value per share for **20 consecutive trading days** within three years of listing[124](index=124&type=chunk)[158](index=158&type=chunk) [Significant Related Party Transactions](index=65&type=section&id=%E9%87%8D%E5%A4%A7%E5%85%B3%E8%81%94%E4%BA%A4%E6%98%93) During the reporting period, the company planned a major asset restructuring to acquire control of Combi-Blocks, Inc. through a share issuance, a matter that progressed from January 2025 but was subsequently terminated by a board resolution on April 14, 2025 - The company had planned to issue shares to acquire a portion of Zhuhai Weibao's equity to gain control of Combi-Blocks, Inc., and raise supporting funds[186](index=186&type=chunk) - This major asset restructuring was terminated by a resolution of the company's board of directors on April 14, 2025[187](index=187&type=chunk) [Significant Contracts and Their Fulfillment](index=67&type=section&id=%E9%87%8D%E5%A4%A7%E5%90%88%E5%90%8C%E5%8F%8A%E5%85%B6%E5%B1%A5%E8%A1%8C%E6%83%85%E5%86%B5) During the reporting period, the company provided guarantees totaling **210 million yuan** to its wholly-owned subsidiary, Shanghai Bilude Pharmaceutical Technology Co., Ltd., to support bank credit lines, with a remaining guarantee balance of **110 million yuan** at period-end Guarantees to Subsidiaries | Guarantor | Guaranteed Party | Guarantee Amount (Million Yuan) | Guarantee Type | | :--- | :--- | :--- | :--- | | Bide Pharma | Shanghai Bilude | 200.00 | Joint and several liability guarantee | | Bide Pharma | Shanghai Bilude | 10.00 | Joint and several liability guarantee | - As of the end of the reporting period, the company's total guarantee balance for its subsidiaries was **110 million yuan**, accounting for **5.64%** of the company's net assets[192](index=192&type=chunk) [Explanation of Progress in Use of Raised Funds](index=70&type=section&id=%E5%8B%9F%E9%9B%86%E8%B5%84%E9%87%91%E4%BD%BF%E7%94%A8%E8%BF%9B%E5%B1%95%E8%AF%B4%E6%98%8E) The company's net proceeds from its initial public offering amounted to **1.309 billion yuan**, with **1.271 billion yuan** cumulatively invested, representing a **97.10%** progress, and all over-raised funds have been fully utilized for repaying bank loans, supplementing working capital, and share repurchases Overall Use of Raised Funds (As of Period End) | Item | Amount (Million Yuan) | | :--- | :--- | | Net Proceeds from Raised Funds | 1,309.00 | | Total Committed Investment | 434.36 | | Total Over-raised Funds | 874.64 | | Total Cumulative Raised Funds Invested | 1,271.07 | | Overall Investment Progress | 97.10% | Details of Over-raised Funds Usage | Purpose | Planned Investment (Million Yuan) | Cumulative Investment (Million Yuan) | Investment Progress (%) | | :--- | :--- | :--- | :--- | | Repayment of Bank Loans and Permanent Working Capital Supplement | 774.64 | 774.64 | 100.00 | | Share Repurchase | 100.00 | 100.00 | 100.00 | | **Total** | **874.64** | **874.64** | **100.00** | Share Changes and Shareholder Information This section details the company's shareholder structure, including the total number of common shareholders and the shareholdings of its top ten shareholders, highlighting the control held by actual controllers and the presence of institutional investors [Shareholder Information](index=77&type=section&id=%E8%82%A1%E4%B8%9C%E6%83%85%E5%86%B5) As of the end of the reporting period, the company had **3,782** common shareholders, with actual controllers Dai Lan and Dai Long holding significant stakes, and institutional investors like China Universal Medical & Health Hybrid Securities Investment Fund also among the top ten shareholders Top Ten Shareholders' Shareholding | Shareholder Name | Number of Shares Held | Proportion (%) | | :--- | :--- | :--- | | Dai Lan | 29,664,719 | 32.64 | | Dai Long | 13,106,289 | 14.42 | | Zhoushan Xinxin Enterprise Management Partnership | 5,019,806 | 5.52 | | Ningbo Landan Venture Capital Partnership | 4,305,076 | 4.74 | | China Universal Medical & Health Hybrid Securities Investment Fund | 4,252,561 | 4.68 | - Actual controllers Dai Lan and Dai Long are siblings and have signed a concerted action agreement; Zhoushan Xinxin, Ningbo Landan, and Wu Bo are concerted parties; Nanxu Investment, Lanyun Wanchi, and Xuqing Investment are employee stock ownership platforms controlled by Dai Long[212](index=212&type=chunk) Bond-Related Information This section confirms the absence of any corporate bonds or non-financial enterprise debt financing instruments issued by the company during the reporting period [Corporate Bonds and Non-Financial Enterprise Debt Financing Instruments](index=82&type=section&id=%E5%85%AC%E5%8F%B8%E5%80%BA%E5%88%B8%E5%92%8C%E9%9D%9E%E9%87%91%E8%9E%8D%E4%BC%81%E4%B8%9A%E5%80%BA%E5%8A%A1%E8%9E%8D%E8%B5%84%E5%B7%A5%E5%85%B7) During the reporting period, the company did not issue any corporate bonds, enterprise bonds, or non-financial enterprise debt financing instruments - The company has no outstanding corporate bonds or convertible corporate bonds[220](index=220&type=chunk) Financial Report This section provides a summary of the company's financial statements, including balance sheet, income statement, and cash flow statement, along with detailed notes explaining key accounting items and their changes [Financial Statement Summary](index=83&type=section&id=%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8%E6%91%98%E8%A6%81) The financial statements indicate a growth in total assets to **2.53 billion yuan** and total liabilities to **581 million yuan**, with the asset-liability ratio rising to **22.98%**, while operating revenue increased by 17.91% to **628 million yuan** and net profit by 41.60% to **73.41 million yuan**, though operating cash flow significantly decreased and investing cash outflow expanded due to wealth management product purchases Consolidated Balance Sheet Summary (Jun 30, 2025) | Item | Period-End Balance (Yuan) | Period-Beginning Balance (Yuan) | | :--- | :--- | :--- | | Cash and Cash Equivalents | 726,936,059.28 | 1,105,333,099.80 | | Trading Financial Assets | 460,896,808.21 | 75,522,082.20 | | Inventories | 850,716,686.81 | 760,217,457.80 | | **Total Assets** | **2,530,189,768.10** | **2,418,035,118.40** | | Short-term Borrowings | 203,152,860.14 | 30,182,470.22 | | **Total Liabilities** | **581,464,113.91** | **390,912,654.76** | | **Equity Attributable to Parent Company Shareholders** | **1,948,725,654.19** | **2,027,122,463.64** | Consolidated Income Statement Summary (Jan-Jun 2025) | Item | Current Period Amount (Yuan) | Prior Period Amount (Yuan) | | :--- | :--- | :--- | | Total Operating Revenue | 627,526,589.12 | 532,207,309.99 | | Total Operating Costs | 522,427,598.32 | 456,333,477.22 | | Total Profit | 100,843,826.91 | 64,254,167.56 | | Net Profit | 73,406,059.54 | 51,839,064.55 | | Net Profit Attributable to Parent Company Shareholders | 73,406,059.54 | 51,839,064.55 | Consolidated Cash Flow Statement Summary (Jan-Jun 2025) | Item | Current Period Amount (Yuan) | Prior Period Amount (Yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 16,112,188.59 | 89,677,429.18 | | Net Cash Flow from Investing Activities | -398,576,339.49 | -266,685,771.14 | | Net Cash Flow from Financing Activities | -7,417,835.52 | -140,764,364.22 | | Period-End Cash and Cash Equivalents Balance | 710,089,200.40 | 947,195,599.76 | [Notes to Consolidated Financial Statements](index=142&type=section&id=%E5%90%88%E5%B9%B6%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8%E9%A1%B9%E7%9B%AE%E6%B3%A8%E9%87%8A) The notes to the financial statements provide detailed explanations of accounting item compositions and changes, highlighting a significant increase in trading financial assets due to wealth management product purchases, low customer concentration in accounts receivable, high inventory proportions, and a substantial rise in short-term borrowings, with revenue broken down by product and channel - Trading financial assets at period-end amounted to **461 million yuan**, a significant increase from **76 million yuan** at the beginning of the period, entirely comprising bank wealth management products[401](index=401&type=chunk) Main Business Revenue by Product Type | Product Type | Operating Revenue (Yuan) | Operating Cost (Yuan) | | :--- | :--- | :--- | | Molecular Building Blocks - Heterocyclic Compounds | 271,473,211.84 | 142,520,031.85 | | Molecular Building Blocks - Benzene Ring Compounds | 146,310,956.15 | 83,918,851.19 | | Molecular Building Blocks - Aliphatic Compounds | 102,671,564.31 | 57,761,085.82 | | Catalysts and Ligands | 66,343,913.92 | 44,956,312.69 | | Life Science Reagents | 40,726,942.90 | 20,684,205.21 | Main Business Revenue by Sales Channel | Sales Channel | Operating Revenue (Yuan) | Operating Cost (Yuan) | | :--- | :--- | :--- | | Direct Sales | 598,706,766.85 | 330,880,293.08 | | Distribution | 28,819,822.27 | 18,960,193.68 |

证券代码：688073 证券简称：毕得医药 公告编号：2025-081 减持计划的主要内容 上海毕得医药科技股份有限公司 因股东自身流动性需求，股东李怡静、陈俊、李黎、杜鹃、李爱飞、耿勇、 蒋亚妹计划根据市场情况拟于本减持计划披露之日起3个交易日后的3个月内通 过集中竞价方式减持其所持有的公司股份，减持数量不超过公司总股本的 1.00%。 其中，李怡静减持公司股份数量不超过 227,854 股，即不超过公司总股本的 0.25%； 1 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 截至本公告披露日，上海毕得医药科技股份有限公司（以下简称"毕得医药" 或"公司"）股东李怡静持有公司无限售条件流通股 374,193 股，占公司股份总 数的 0.41%。股东陈俊持有公司无限售条件流通股 224,515 股，占公司股份总数 的 0.25%。股东李黎持有公司无限售条件流通股 224,515 股，占公司股份总数的 0.25%。股东杜鹃持有公司无限售条件流通股 224 ...

每经AI快讯，9月12日，毕得医药(688073.SH)公告称，股东李怡静、陈俊、李黎、杜鹃、李爱飞、耿 勇、蒋亚妹计划根据市场情况拟于本减持计划披露之日起3个交易日后的3个月内通过集中竞价方式减持 其所持有的公司股份，减持数量不超过公司总股本的1.00%。 ...

国泰海通证券股份有限公司 关于上海毕得医药科技股份有限公司 2025 年半年度持续督导跟踪报告 | 保荐机构名称：国泰海通证券股份有限公司 | 被保荐公司简称：毕得医药 | | --- | --- | | 保荐代表人姓名：雷浩、李华东 | 被保荐公司代码：688073.SH | 重大事项提示 经中国证券监督管理委员会《关于同意上海毕得医药科技股份有限公司首次 公开发行股票注册的批复》（证监许可[2022]1885 号）批复，上海毕得医药科技 股份有限公司（以下简称"上市公司"、"公司"或"发行人"）首次公开发行股票 1,622.9100 万股，每股面值人民币 1 元，每股发行价格人民币 88.00 元，募集资 金总额为人民币 142,816.08 万元，扣除发行费用后，实际募集资金净额为人民币 130,899.89 万元。本次发行证券已于 2022 年 10 月 11 日在上海证券交易所上市。 国泰海通证券股份有限公司（以下简称"保荐机构"或"国泰海通"）担任其持续督 导保荐机构，持续督导期间为 2022 年 10 月 11 日至 2025 年 12 月 31 日。 在 2025 年 1 月 1 日至 202 ...

截至发稿，曹阳累计任职时间1年364天，现任基金资产总规模1275.43万元，任职期间最佳基金回报 44.37%， 任职期间最差基金回报-33.52%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 资料显示，上海毕得医药科技股份有限公司位于上海市杨浦区翔殷路999号3幢6层，成立日期2007年4月 27日，上市日期2022年10月11日，公司主营业务涉及聚焦于新药研发产业链前端,依托药物分子砌块的 研发设计、生产及销售等核心业务,能够为新药研发机构提供结构新颖、功能多样的药物分子砌块及科 学试剂等产品。主营业务收入构成为：分子砌块杂环化合物43.26%，分子砌块苯环化合物23.32%，分 子砌块脂肪族类化合物16.36%，催化剂和配体10.57%，生命科学试剂6.49%。 责任编辑：小浪快报 从基金十大重仓股角度 红塔红土医药精选股票发起式A（020331）成立日期2024年4月2日，最新规模1166.63万。今年以来收益 40.01%，同类排名511/4222；近一 ...

Group 1 - Bid Pharma's stock price decreased by 5.26% to 62.38 CNY per share, with a trading volume of 73.24 million CNY and a turnover rate of 2.63%, resulting in a total market capitalization of 5.669 billion CNY [1] - The company focuses on the front end of new drug research and development, providing innovative drug molecular building blocks and scientific reagents [1] - The main revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from molecular building block aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1] Group 2 - Hongta Hongtu Fund has a significant holding in Bid Pharma, with the Hongta Hongtu Medical Selected Stock Fund A (020331) reducing its position by 157 shares, holding a total of 11,300 shares, which accounts for 5.16% of the fund's net value [2] - The fund has experienced a year-to-date return of 45.4% and a one-year return of 57.15%, ranking 377 out of 4222 and 1498 out of 3798 respectively [2] - The fund manager, Cao Yang, has been in position for 1 year and 363 days, with the fund's total asset size at 12.7543 million CNY and a best return of 44.37% during his tenure [3]

Core Viewpoint - Bid Pharma's stock price has shown a year-to-date increase of 33.56%, but has recently experienced a decline of 4.59% over the past five trading days, indicating volatility in its performance [1]. Company Overview - Bid Pharma, established on April 27, 2007, and listed on October 11, 2022, is located in Yangpu District, Shanghai. The company focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1]. - The company's main business revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from molecular building block aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1]. Financial Performance - For the first half of 2025, Bid Pharma achieved an operating income of 628 million yuan, representing a year-on-year growth of 17.91%. The net profit attributable to shareholders was 73.41 million yuan, reflecting a year-on-year increase of 41.60% [2]. - Since its A-share listing, Bid Pharma has distributed a total of 258 million yuan in dividends [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders for Bid Pharma increased by 4.76% to 3,782, while the average circulating shares per person decreased by 4.55% to 11,431 shares [2]. - Among the top ten circulating shareholders, notable changes include: - China Europe Medical Health Mixed A (003095) as the second-largest shareholder, holding 4.2526 million shares, down by 193,100 shares from the previous period - Agricultural Bank of China Medical Health Stock (000913) as the fourth-largest shareholder, holding 841,000 shares, up by 177,500 shares - New entrants include Guangfa Xinxing Mixed A (002132) and Changxin Jinli Trend Mixed A (519994) [3].

Core Viewpoint - The major shareholders of Shanghai Bid Pharmaceutical Technology Co., Ltd. plan to reduce their holdings due to liquidity needs, with specific details on the number of shares and methods of reduction outlined in the announcement [1][2]. Shareholding Structure - As of the announcement date, major shareholder Zhoushan Xinxie Enterprise Management Partnership holds 5,019,806 shares, accounting for 5.52% of the total shares. Ningbo Landan Enterprise Management Partnership holds 4,305,076 shares, representing 4.74%, with 69,486 shares being subject to restrictions. Shareholder Wu Bo holds 785,804 shares, making up 0.86% of the total shares. Together, these shareholders hold a total of 11.12% of the company [1][2]. Reduction Plan Details - Zhoushan Xinxie plans to reduce up to 908,829 shares (1.00% of total shares) through block trading, while Ningbo Landan also plans to reduce up to 908,829 shares (1.00%). Wu Bo intends to reduce up to 785,804 shares (0.86%) through centralized bidding. The reduction prices will be determined based on market conditions at the time of the sale [2][3]. Shareholder Commitments - The major shareholders have made commitments regarding their shareholding, including a lock-up period of 12 months post-IPO during which they will not transfer or manage their shares. After this period, any reduction within 24 months will be based on market prices and not below the issue price [5][6][8]. Compliance with Regulations - The reduction plan complies with relevant laws and regulations, including the Securities Law and the Shanghai Stock Exchange rules. The shareholders are committed to adhering to these regulations and will disclose their reduction plans three trading days in advance [7][9][13].